Unfortunately, since the trials on agalsidase-alfa and agalsidase-beta have been authorized by the European Medicines Agency (EMA), no clear evidence has emerged that ERT alters the natural course of Fabry disease-associated cardiac or cerebrovascular disease or nephropathy, in particular when late diagnosis is the case. Here, GLA is linked to Fabry disease.